[go: up one dir, main page]

WO2015133771A1 - Nouveau biomarqueur pour neurogliome et son utilisation - Google Patents

Nouveau biomarqueur pour neurogliome et son utilisation Download PDF

Info

Publication number
WO2015133771A1
WO2015133771A1 PCT/KR2015/001961 KR2015001961W WO2015133771A1 WO 2015133771 A1 WO2015133771 A1 WO 2015133771A1 KR 2015001961 W KR2015001961 W KR 2015001961W WO 2015133771 A1 WO2015133771 A1 WO 2015133771A1
Authority
WO
WIPO (PCT)
Prior art keywords
glioma
stanniocalcin
protein
nucleic acid
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2015/001961
Other languages
English (en)
Korean (ko)
Inventor
이태훈
윤종혁
김재윤
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novacell Technology Inc
Original Assignee
Novacell Technology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novacell Technology Inc filed Critical Novacell Technology Inc
Publication of WO2015133771A1 publication Critical patent/WO2015133771A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Definitions

  • Prior literatures related to glioma diagnostic markers include Korean Patent No. 1,324,773, which provides information on a method for diagnosing glioma, characterized by examining the expression rate of GFR ⁇ 4 (GDNF receptor alpha 4) on the cell membrane and endoplasmic reticulum.
  • GFR ⁇ 4 GDNF receptor alpha 4
  • scFv refers to a recombinant chain fragment that is prepared as a single chain fragment variable in a single chain using variable linkers (V H and V L ) in the Fab of the antibody. do.
  • sdAb single doamain antibody
  • sdAb single doamain antibody
  • a “diabody” is a divalent double that is made to shorten the linker length between V H and V L of the scFv (5 aa) so that the two scFvs form dimers with each other.
  • Recombinant antibody fragments with bispesific are known to have higher antigen specificity than conventional scFv.
  • a pharmaceutical composition for treating glioma comprising a Stanniocalcin inhibitor as an active ingredient that inhibits Stanniocalcin protein function or expression of the gene encoding the Stanniocalcin protein.
  • the glioma may be non-malignant glioma, primary glioma, metastatic glioma or malignant glioma of stage III or IV.
  • a method of treating glioma comprising administering to a glioma patient a Stanniocalcin inhibitor which inhibits the function of a Stanniocalcin protein or expression of a gene encoding the Stanniocalcin protein. This is provided.
  • the inventors performed an in vitro scratch wound assay to identify new functions for Stanniocalcin 1, 2 in the identified proteins.
  • the present inventors dispensed glioma (U373MG) cells in a 60 mm cell culture plate, and when glioma cells were 80% full, transfected pCMV2-STC1 and pCMV2-STC2 for 4 hours each by 1 ug to Stanniocalcin 1, 2 was overexpressed and scratched after 24 hours for analysis.
  • overexpression of Stanniocalcin 1, 2 was confirmed that the movement of U373MG cells in the normal oxygen state compared to the control (Fig. 4A).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Mycology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne un nouveau biomarqueur pour neurogliome et son utilisation, et plus spécifiquement, une composition permettant de diagnostiquer un neurogliome comprenant une molécule d'acide nucléique codant une protéine stanniocalcine, une molécule d'acide nucléique complémentaire qui est complémentaire de la molécule d'acide nucléique, un fragment de la molécule d'acide nucléique, un fragment de la molécule d'acide nucléique complémentaire, ou un aptamère ou un anticorps qui se lie spécifiquement à la protéine stanniocalcine, ou un fragment fonctionnel de l'anticorps ; et un procédé de traitement de neurogliome qui cible la protéine stanniocalcine.
PCT/KR2015/001961 2014-03-06 2015-02-27 Nouveau biomarqueur pour neurogliome et son utilisation Ceased WO2015133771A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020140026428A KR101727026B1 (ko) 2014-03-06 2014-03-06 신규 신경교종의 바이오마커 및 그의 용도
KR10-2014-0026428 2014-03-06

Publications (1)

Publication Number Publication Date
WO2015133771A1 true WO2015133771A1 (fr) 2015-09-11

Family

ID=54055522

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2015/001961 Ceased WO2015133771A1 (fr) 2014-03-06 2015-02-27 Nouveau biomarqueur pour neurogliome et son utilisation

Country Status (2)

Country Link
KR (1) KR101727026B1 (fr)
WO (1) WO2015133771A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116718784A (zh) * 2023-06-19 2023-09-08 十堰市太和医院（湖北医药学院附属医院） Stc1作为胶质瘤标记物的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001030969A2 (fr) * 1999-10-27 2001-05-03 Human Genome Sciences, Inc. Proteines et acides nucleiques de stanniocalcine et methodes afferentes
US20070134670A1 (en) * 2003-12-12 2007-06-14 Bayer Pharmaceuticals Corporation Methods for prediction and prognosis of cancer, and monitoring cancer therapy
US20100062002A1 (en) * 2002-08-15 2010-03-11 Genzyme Corporation Brain Endothelial Cell Expression Patterns

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001030969A2 (fr) * 1999-10-27 2001-05-03 Human Genome Sciences, Inc. Proteines et acides nucleiques de stanniocalcine et methodes afferentes
US20100062002A1 (en) * 2002-08-15 2010-03-11 Genzyme Corporation Brain Endothelial Cell Expression Patterns
US20070134670A1 (en) * 2003-12-12 2007-06-14 Bayer Pharmaceuticals Corporation Methods for prediction and prognosis of cancer, and monitoring cancer therapy

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WONG, C. K. C. ET AL.: "Effects of dibutyryl cAMP on stanniocalcin and stanniocalcin- related protein mRNA expression in neuroblastoma cells.", JOURNAL OF ENDOCRINOLOGY., vol. 173, 2002, pages 199 - 209, XP055223086 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116718784A (zh) * 2023-06-19 2023-09-08 十堰市太和医院（湖北医药学院附属医院） Stc1作为胶质瘤标记物的应用

Also Published As

Publication number Publication date
KR20150105504A (ko) 2015-09-17
KR101727026B1 (ko) 2017-04-17

Similar Documents

Publication Publication Date Title
Karagiannis et al. Proteomic signatures of the desmoplastic invasion front reveal collagen type XII as a marker of myofibroblastic differentiation during colorectal cancer metastasis
CN103975078B (zh) 治疗和诊断膀胱癌的方法和组合物
EP2999797B1 (fr) Isoformes spécifiques de gata6 et nkx2-1 en tant que nouveaux marqueurs pour les approches de diagnostic et de thérapie du cancer et en tant que cibles pour la thérapie anticancéreuse
US20140221244A1 (en) Methods and Compositions for the Treatment and Diagnosis of Colorectal Cancer
Zhong et al. LRG1 modulates invasion and migration of glioma cell lines through TGF-β signaling pathway
EP3008210B1 (fr) Procédés pour détecter le cancer de la prostate
Li et al. MALAT1 downregulation is associated with polycystic ovary syndrome via binding with MDM2 and repressing P53 degradation
Chen et al. A novel invasive-related biomarker in three subtypes of nonfunctioning pituitary adenomas
CN114457163B (zh) 一种间充质亚型胶质母细胞瘤的标志物及其应用
Zhou et al. Neddylation pathway promotes myeloid-derived suppressor cell infiltration via NF-κB-mCXCL5 signaling in lung cancer
WO2016152352A1 (fr) Biomarqueur spécifique du mélanome et son utilisation
CN113876953B (zh) 新型细胞衰老干预靶点及其在化疗抗癌中的靶向应用
US8980638B2 (en) Use of IMP3 as a prognostic marker for cancer
WO2015133771A1 (fr) Nouveau biomarqueur pour neurogliome et son utilisation
WO2016008051A1 (fr) Contactine-1 (cntn1) pour utilisation dans des procédés de diagnostic et de traitement du cancer de la prostate
CN111910005B (zh) Cdk4/6抑制剂敏感性相关基因及其应用
Jaroszewski et al. Anaplastic thyroid cancer cell-secreted TGFβ1 plays a key role in inducing macrophage polarization of human monocytes
US20230375571A1 (en) Gdf3 as biomarker and biotarget in post-ischemic cardiac remodeling
Jifu et al. ZNF516 suppresses stem cell-like characteristics by regulating the transcription of Sox2 in colorectal cancer
US20220017971A1 (en) Composition for predicting chemotherapy resistance of ovarian cancer and use thereof
US20180209979A1 (en) Method for individualized cancer therapy
WO2015133772A1 (fr) Nouveau biomarqueur pour le cancer colorectal et agent anticancéreux le ciblant
KR102687764B1 (ko) miR-214-3p를 포함하는 난소암에 대한 화학요법제의 저항성 예측용 조성물
CN111961727A (zh) miR-588及其靶基因在胃癌中的应用
KR102882636B1 (ko) 유두상 갑상선암 진단 또는 예측용 mrpl14 유전자 마커 및 이의 용도

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15758825

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15758825

Country of ref document: EP

Kind code of ref document: A1